Medical Marijuana Use in HIV+ Patients Prospective Cohort Study

NCT ID: NCT01536899

Last Updated: 2018-04-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

119 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-02-29

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators are interested in understanding personal factors such as medical conditions and mental health, as well as social and economic factors, that influence marijuana (and other substance) use in HIV-positive patients.

Several alternative hypotheses will be evaluated in the proposed project:

1. healthier patients may self-select marijuana use;
2. marijuana use may be associated with consequences that create barriers to seeking healthcare;
3. marijuana use may have medicinal value that reduces the need for such care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will involve a total of 5 interviews with clinical research staff members, the total involvement will be for about 1 year.

The first interview will establish a baseline of current behaviors and health status; this will take about 3-4 hours. This interview will take place at the Tolan Park Medical Building, located at 3901 Chrysler Service Dr. The remaining 4 interviews - which will be shorter in length - will be conducted about 3, 6, 9, and 12 months after the baseline interview; each follow-up interview will take about 2 hours.The purpose of the 4 remaining interviews is to assess changes in behaviors and health status over time.

We will collect urine samples at each of the 5 interview sessions to assess health and illicit drug use.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Positive Marijuana Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants will be patients in the HIV clinic.
* Participants will have HIV.
* Participants will sign a single consent form.
* Participants will be marijuana users.

Exclusion Criteria

* Participants who test negative for marijuana will be excluded.
* Volunteers who exhibit signs of drug intoxication or cognitive/mental impairment during the consent process will be excluded.
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

Wayne State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mark Greenwald, PhD

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark Greenwald, PhD

Role: PRINCIPAL_INVESTIGATOR

Wayne State University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wayne State University (HIV clinic, Tolan Park Medical Buiding)

Detroit, Michigan, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Woodcock EA, Greenwald MK, Chen I, Feng D, Cohn JA, Lundahl LH. HIV chronicity as a predictor of hippocampal memory deficits in daily cannabis users living with HIV. Drug Alcohol Depend Rep. 2023 Sep 13;9:100189. doi: 10.1016/j.dadr.2023.100189. eCollection 2023 Dec.

Reference Type DERIVED
PMID: 37736522 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R01DA032678

Identifier Type: NIH

Identifier Source: secondary_id

View Link

MMC-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oral Dronabinol-HIV
NCT06034314 ACTIVE_NOT_RECRUITING PHASE1